- Brands
- Offerings
- Diagnostic Panels
- Knowledge Center
- Diagnostics
Abbott’s booth will bring you new ways to achieve measurably better healthcare performance with our personalized core diagnostics solutions consisting of Resourceful Advocates, Harmonized Systems and Intelligent Insights.
You’re invited to an exciting experience celebrating 50 years of diagnostic innovation that helps you enhance patient care now and into the future.
As your lab is adapting to the demands of increased testing volumes, enhanced assay performance, and turnaround expectations, it's important to have a flexible automation option.
With your lab in mind, the GLP Systems is designed to provide:
This year, experience one-on-one or group demonstrations to learn about our latest offerings. During the product demonstrations, you can explore Abbott's next generation of Alinity systems, designed to simplify diagnostics and help deliver results. Demonstrations for GLP systems Track*, AlinIQ Digital Health Solutions, Hematology, Molecular, Diabetes Care and Point of Care are also available.
As a leader in diagnostic innovation for 50 years, hear how we continue to evolve during our three scientific workshops.
Sign Up for Demos and Workshops
Join us in our booth for innovation in action with educational MED Talks, a comprehensive series of trending topics led by industry experts in partnership with top researchers, collaborators, and key opinion leaders.
Topic | Speaker/moderator | time |
TUESDAY, JULY 26 | ||
Biomarkers of Brain Injury; Early Experiences to Advance Care |
Moderator: Dr. Chris Davlantes Speaker: Dr. Carmen Gherasim |
10:30am |
Making the Transition to HsTnI: Critical Challenges and Solutions |
Moderator: Dr. Gillian Murtagh Speaker: Dr. Chris Farnsworth Speaker: Dr. Jon Gronbach |
11:30am |
The Evolution of Artificial Intelligence and Machine Learning in Laboratory Medicine. Where do we go from here? |
Moderator: Dr. Randal Schneider Speaker: Dr. Daniel Herman Speaker: Dr. Thomas Durant |
12:30pm |
From R&D to Operational Excellence: New advancements in Molecular Diagnostics |
Moderator: Dr. Klara Abravaya, DVP, R&D Abbott Speaker: Michael Flores, |
2:00pm |
Traumatic Brain Injury : Fact or Fiction? |
Moderator: Dr. Chris Davlantes Moderator: Dr. Beth McQuiston Speaker: Angela Lauster |
3:00pm |
WEDNESDAY, JULY 27 |
||
The Forefront of Innovation Using Biomarkers of Brain Injury |
Moderator: Dr. Chris Davlantes Speaker: Angela Lauster |
10:30am |
How the Abbott Pandemic Defense Coalition Stops Viruses in Their Tracks to Prevent The Next Pandemic |
Moderator: Dr. Alexander Carterson Speaker: Dr. Mary Rodgers |
11:30am |
From HBsAg to HIV: 50 Years of Innovation |
Moderator: Dr. Alexander Carterson Speaker: Dr. John Hackett Speaker: Dr. Oliver Laeyendecker |
12:30pm |
New Innovations and Benefits through Optimized Quality Control |
Moderator: Dr. Ramani Wonderling Speaker: Kevin Williams, Lab Supervisor |
2:00pm |
Cutting-edge experiences: Early feedback from i-STAT TBI Plasma Users |
Moderator: Dr. Chris Davlantes Speaker: Angela Lauster Speaker: Carmen Gherasim, |
3:00pm |
Posters can be viewed from 9:30 a.m. – 5 p.m. Authors will be at available for discussion next to their posters from 1:30 – 2:30 p.m. on Tuesday, July 26 and Wednesday, July 27.
poster title | Presenting author | poster number |
TUESDAY, JULY 26 | ||
Analytical Performance Assessment of a Newly Formulated, IFCC traceable Alkaline Phosphatase Assay for Abbott’s ARCHITECT c and Alinity c Systems | J. Sheldon | A-076 |
Development of Exploratory Algorithms using Plasma Biomarkers on ARCHITECT i2000 and c8000 Platforms, Demographic, and Radiomic Data to Aid in Risk of Malignancy Prediction of Indeterminate Pulmonary Nodules | N. Jeanblanc | A-041 |
Research Use Only (RUO) IgG1 and IgG2 Subclass Assays on the Abbott Alinity c Clinical Chemistry Analyzer | N. Jeanblanc | A-042 |
Improved accuracy across the analytical measuring range for the newly formulated Calcium assay on Abbott’s ARCHITECT and Alinity c Systems | S. Syed | A-081 |
Stability Performance Impact of Clinical Chemistry Enzyme Assays Prepared in Stainless Steel Containers | S. Syed | A-082 |
Improved Analytical Measuring Interval and Hemoglobin performance for New Investigational Use Assay (IUO) Triglyceride Assay on the Abbott’s ARCHITECT and Alinity c Systems | S. Ali | A-004 |
Improved hemoglobin interference performance on newly formulated Cholesterol assay for Abbott’s ARCHITECT and Alinity c systems. | H. Soni | A-078 |
Pre-analytical Characterization of Nasal and Nasopharyngeal Specimen CoV2 Antigen Stability in Transport Media | C. Jacobson | A-040 |
Reagent Lot Consistency of Three Common Cardiac Markers on Alinity i | K. Johnson | A-044 |
Evaluation of Reagent Lot-to-Lot Performnace of Alinity i Tumor Marker Assays | K. Johnson | A-043 |
A Pre-treatment free and Highly Selective Chromogenic Research Use Only (RUO) assay for Zinc deficiency on the Abbott Alinity c System | L. Ruvuna | A-071 |
Pediatric reference interval verification for special chemistry, immunoassay, and cancer markers on the Abbott Alinity ci system | M.K. Bohn | A-242 |
Serological Antibody Response to SARS-CoV-2 Vaccination in a Large Cohort of Canadian Children, Adolescents, and Adults | M.K. Bohn | A-244 |
WEDNESDAY, JULY 27 | ||
Development of the hCG+β immunoassay standardized to the 6th WHO International Standard for hCG for Abbott’s Alinity i® analyzer | K. Holman | B-038 |
Analytical performance evaluation of the next generation Clinical Chemistry assays on the ARCHITECT system | H. Ren | B-067 |
Longitudinal post immunisation serology of covid 19 using the Abbott Alinity SARS-CoV-2 IgG II quantitative assay | I. Piec | B-227 |
Measurement of HbA1c in Packed Red Blood Cells using the Abbott Hemoglobin A1c assay | P. Henriques | B-037 |
Evaluation of Hemoglobin variants in the Abbott Alinity c HbA1c assay | J. Nichols | B-171 |
Development of a Prototype SARS-CoV-2 Antigen ARCHITECT Automated Immunoassay | P. Hemken | B-199 |
Performance Evaluation of Abbott Neuron-Specific Enolase (NSE) Assay on Alinity and ARCHITECT Systems | C. Chen | B-015 |
Multi-center Performance Evaluation of the HSV-1 IgG and HSV-2 IgG Assays* on the ARCHITECT i2000SR System | A. Martinez | B-221 |
Evaluation of the ARCHITECT Toxo IgG and Alinity i Toxo IgG Assays for the US Market | W. Krack | B-213 |
Comparison of Two NT-ProBNP assays | D. Daghfal | B-018 |
18-Month Trends of SARS-CoV-2 Anti-Spike IgG Antibodies Among Healthcare Workers | Y. Kataria | TBA |
SARS-CoV-2 Seroprevalence in Rhode Island Pregnancies in Early 2020 | R. Schneider | B-236 |
First pass efficiency of Alinity hq compared to Sysmex XN-10 | S. Silvia | B-176 |
Morphological flagging of Alinity hq compared with Siemens Advia 2120 in a tertiary care pediatric hospital | S. Silvia | B-177 |
Build key laboratory competencies and explore topics from various disciplines with our learning guides.
Find the latest information in laboratory science, therapeutic areas and Abbott innovation.
Watch the webinar to hear from experts how you can realize the value within and beyond your laboratory walls with a TVO approach.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.